Difference between revisions of "Template:Available forms of progesterone"
Jump to navigation
Jump to search
Template documentation
imported>CV9933 (tweak cite "Drugs@FDA" for transclusion) |
imported>Medgirl131 (Further compact + improve appearance.) |
||
| Line 1: | Line 1: | ||
| − | {| class="wikitable sortable floatright plainrowheaders" style="text-align:left; margin-left:auto; margin-right:auto; border:none; | + | {| class="wikitable sortable floatright plainrowheaders" style="width:465px; font-size:small; text-align:left; margin-left:auto; margin-right:auto; border:none;" |
|+ class="nowrap" | {{Navbar|Available forms of progesterone|mini=y}} Available forms of [[progesterone (medication)|progesterone]]{{refn|group=sources|'''Sources:''' <ref name="Drugs@FDA">{{cite web |title=Drugs@FDA: FDA Approved Drug Products |publisher=United States Food and Drug Administration |accessdate=26 July 2018 |url=http://www.accessdata.fda.gov/scripts/cder/daf/}}</ref> | |+ class="nowrap" | {{Navbar|Available forms of progesterone|mini=y}} Available forms of [[progesterone (medication)|progesterone]]{{refn|group=sources|'''Sources:''' <ref name="Drugs@FDA">{{cite web |title=Drugs@FDA: FDA Approved Drug Products |publisher=United States Food and Drug Administration |accessdate=26 July 2018 |url=http://www.accessdata.fda.gov/scripts/cder/daf/}}</ref> | ||
<ref name="EngelKleemann2014">{{cite book| vauthors = Engel J, Kleemann A, Kutscher B, Reichert D |title=Pharmaceutical Substances, 5th Edition, 2009: Syntheses, Patents and Applications of the most relevant APIs|url=https://books.google.com/books?id=4lCGAwAAQBAJ&pg=PA1145|date=14 May 2014|publisher=Thieme|isbn=978-3-13-179275-4|pages=1145–}}</ref><ref name="Becker2001">{{cite book| first = Kenneth L. | last = Becker | name-list-format = vanc |title=Principles and Practice of Endocrinology and Metabolism |url=https://books.google.com/books?id=FVfzRvaucq8C&pg=PA2168|year=2001|publisher=Lippincott Williams & Wilkins|isbn=978-0-7817-1750-2|pages=2168–}}</ref><ref name="MVJain2018">{{cite book| vauthors = Anita MV, Jain S, Goel N |title=Use of Progestogens in Clinical Practice of Obstetrics and Gynecology|url=https://books.google.com/books?id=VrpEDwAAQBAJ&pg=PA4|date=31 July 2018|publisher=JP Medical Ltd|isbn=978-93-5270-218-3|pages=4–}}</ref><ref name="Sauer2013">{{cite book | first = Mark V. | last = Sauer | name-list-format = vanc |title=Principles of Oocyte and Embryo Donation|url=https://books.google.com/books?id=LUpDAAAAQBAJ&pg=PA7|date=1 March 2013|publisher=Springer Science & Business Media|isbn=978-1-4471-2392-7|pages=7,117–118}}</ref><ref name="ElderDale2010">{{cite book| vauthors = Elder K, Dale B |title=In-Vitro Fertilization|url=https://books.google.com/books?id=JXV6eYd8RwwC&pg=PA26|date=2 December 2010|publisher=Cambridge University Press|isbn=978-1-139-49285-0|pages=26–}}</ref><ref name="P.R.-Vademecum-ProSphere">https://web.archive.org/web/20191230051017/https://mx.prvademecum.com/medicamento/prosphere-11003/</ref><ref name="Kahr2013">{{cite book|author=Heinrich Kahr|title=Konservative Therapie der Frauenkrankheiten: Anzeigen, Grenzen und Methoden Einschliesslich der Rezeptur|url=https://books.google.com/books?id=Hte1BgAAQBAJ&pg=PA21|date=8 March 2013|publisher=Springer-Verlag|isbn=978-3-7091-5694-0|pages=21–}}</ref><ref name="Schering1962">{{cite book|title=Basic Sex Hormone Therapy|url=https://books.google.com/books?id=uJrIvQEACAAJ|year=1962|publisher=Schering A.G.|page=96}}</ref><ref name="CurrMedDrugs1962">{{cite book|title=Current Medicine and Drugs|url=https://books.google.com/books?id=auc1AQAAIAAJ|year=1962|page=40|quote=Primolut Intravenous (Schering A.G. Berlin)}}</ref><ref name="HaleemKhan2015">{{cite journal | vauthors = Haleem S, Khan MI | title = Changing Indian Market Trends of NMP: A Review | journal = International Journal of Pharma Research & Review | volume = 4 | issue = 3 | pages = 28–30 | date = March 2015 | issn = 2278-6074 | url = https://web.archive.org/web/20200819053823/https://pdfs.semanticscholar.org/a232/3b1d613fd8f767c35b81d74a302e779ed749.pdf}}</ref>}}{{efn|group=progforms|This table only includes products where progesterone is the sole active ingredient.}} | <ref name="EngelKleemann2014">{{cite book| vauthors = Engel J, Kleemann A, Kutscher B, Reichert D |title=Pharmaceutical Substances, 5th Edition, 2009: Syntheses, Patents and Applications of the most relevant APIs|url=https://books.google.com/books?id=4lCGAwAAQBAJ&pg=PA1145|date=14 May 2014|publisher=Thieme|isbn=978-3-13-179275-4|pages=1145–}}</ref><ref name="Becker2001">{{cite book| first = Kenneth L. | last = Becker | name-list-format = vanc |title=Principles and Practice of Endocrinology and Metabolism |url=https://books.google.com/books?id=FVfzRvaucq8C&pg=PA2168|year=2001|publisher=Lippincott Williams & Wilkins|isbn=978-0-7817-1750-2|pages=2168–}}</ref><ref name="MVJain2018">{{cite book| vauthors = Anita MV, Jain S, Goel N |title=Use of Progestogens in Clinical Practice of Obstetrics and Gynecology|url=https://books.google.com/books?id=VrpEDwAAQBAJ&pg=PA4|date=31 July 2018|publisher=JP Medical Ltd|isbn=978-93-5270-218-3|pages=4–}}</ref><ref name="Sauer2013">{{cite book | first = Mark V. | last = Sauer | name-list-format = vanc |title=Principles of Oocyte and Embryo Donation|url=https://books.google.com/books?id=LUpDAAAAQBAJ&pg=PA7|date=1 March 2013|publisher=Springer Science & Business Media|isbn=978-1-4471-2392-7|pages=7,117–118}}</ref><ref name="ElderDale2010">{{cite book| vauthors = Elder K, Dale B |title=In-Vitro Fertilization|url=https://books.google.com/books?id=JXV6eYd8RwwC&pg=PA26|date=2 December 2010|publisher=Cambridge University Press|isbn=978-1-139-49285-0|pages=26–}}</ref><ref name="P.R.-Vademecum-ProSphere">https://web.archive.org/web/20191230051017/https://mx.prvademecum.com/medicamento/prosphere-11003/</ref><ref name="Kahr2013">{{cite book|author=Heinrich Kahr|title=Konservative Therapie der Frauenkrankheiten: Anzeigen, Grenzen und Methoden Einschliesslich der Rezeptur|url=https://books.google.com/books?id=Hte1BgAAQBAJ&pg=PA21|date=8 March 2013|publisher=Springer-Verlag|isbn=978-3-7091-5694-0|pages=21–}}</ref><ref name="Schering1962">{{cite book|title=Basic Sex Hormone Therapy|url=https://books.google.com/books?id=uJrIvQEACAAJ|year=1962|publisher=Schering A.G.|page=96}}</ref><ref name="CurrMedDrugs1962">{{cite book|title=Current Medicine and Drugs|url=https://books.google.com/books?id=auc1AQAAIAAJ|year=1962|page=40|quote=Primolut Intravenous (Schering A.G. Berlin)}}</ref><ref name="HaleemKhan2015">{{cite journal | vauthors = Haleem S, Khan MI | title = Changing Indian Market Trends of NMP: A Review | journal = International Journal of Pharma Research & Review | volume = 4 | issue = 3 | pages = 28–30 | date = March 2015 | issn = 2278-6074 | url = https://web.archive.org/web/20200819053823/https://pdfs.semanticscholar.org/a232/3b1d613fd8f767c35b81d74a302e779ed749.pdf}}</ref>}}{{efn|group=progforms|This table only includes products where progesterone is the sole active ingredient.}} | ||
|- | |- | ||
| − | ! scope="col | + | ! scope="col" | Route/form |
| − | ! scope="col | + | ! scope="col" | Dose |
| − | ! scope="col | + | ! scope="col" | Brand name |
| − | ! scope="col | + | ! scope="col" | Availability{{efn|group=progforms|See also: [[Progesterone (medication)#Availability|Progesterone (medication) § Availability]]}} |
|- | |- | ||
! scope="row" style="background:#f8f9fa;" | [[Oral administration|Oral]] capsule | ! scope="row" style="background:#f8f9fa;" | [[Oral administration|Oral]] capsule | ||
| Line 27: | Line 27: | ||
|- | |- | ||
! scope="row" style="background:#f8f9fa;" | [[Vaginal administration|Vaginal]] gel | ! scope="row" style="background:#f8f9fa;" | [[Vaginal administration|Vaginal]] gel | ||
| − | | 4 | + | | 4, 8% (45, 90 mg) || Crinone{{efn|group=progforms|name=others}} || Widespread |
|- | |- | ||
! scope="row" style="background:#f8f9fa;" | [[Vaginal administration|Vaginal]] suppository | ! scope="row" style="background:#f8f9fa;" | [[Vaginal administration|Vaginal]] suppository | ||
| Line 44: | Line 44: | ||
| 2, 5, 10, 20, 25,<br />50, 100 mg/mL || Proluton{{efn|group=progforms|name=others}} || Widespread | | 2, 5, 10, 20, 25,<br />50, 100 mg/mL || Proluton{{efn|group=progforms|name=others}} || Widespread | ||
|- | |- | ||
| − | ! scope="row" style="background:#f8f9fa;" | IM ({{abbr|aq.|aqueous}} | + | ! scope="row" style="background:#f8f9fa;" | IM ({{abbr|aq. susp.|aqueous suspension}}) |
| − | | 12.5, 30, 100 mg/mL || Agolutin{{efn|group=progforms|name=others}} || Europe{{efn|group=progforms|Specifically the Czech Republic and Slovakia.}} | + | | style="font-size: 90%;" | 12.5, 30, 100 mg/mL || Agolutin{{efn|group=progforms|name=others}} || Europe{{efn|group=progforms|Specifically the Czech Republic and Slovakia.}} |
|- | |- | ||
! scope="row" style="background:#f8f9fa;" | IM (emulsion) | ! scope="row" style="background:#f8f9fa;" | IM (emulsion) | ||
Revision as of 14:40, 2 October 2020
| Route/form | Dose | Brand name | Availability[lower-alpha 2] |
|---|---|---|---|
| Oral capsule | 100, 200, 300 mg | Prometrium[lower-alpha 3] | Widespread |
| Oral tablet (SR) | 200, 300, 400 mg | Dubagest SR[lower-alpha 3] | India |
| Sublingual tablet | 10, 25, 50, 100 mg | Luteina[lower-alpha 3] | Europe[lower-alpha 4] |
| Transdermal gel[lower-alpha 5] | 1% (25 mg) | Progestogel | Europe |
| Vaginal capsule | 100, 200 mg | Utrogestan | Widespread |
| Vaginal tablet | 100 mg | Endometrin[lower-alpha 3] | Widespread |
| Vaginal gel | 4, 8% (45, 90 mg) | Crinone[lower-alpha 3] | Widespread |
| Vaginal suppository | 200, 400 mg | Cyclogest | Europe |
| Vaginal ring | 10 mg/day[lower-alpha 6] | Fertiring[lower-alpha 3] | South America[lower-alpha 7] |
| Rectal suppository | 200, 400 mg | Cyclogest | Europe |
| Intrauterine device | 38 mg | Progestasert | Discontinued |
| IM (oil solution) | 2, 5, 10, 20, 25, 50, 100 mg/mL |
Proluton[lower-alpha 3] | Widespread |
| IM (aq. susp.) | 12.5, 30, 100 mg/mL | Agolutin[lower-alpha 3] | Europe[lower-alpha 8] |
| IM (emulsion) | 5, 10, 25 mg/mL | Di-Pro-Emulsion | Discontinued |
| IM (microsphere) | 20, 100 mg/mL | ProSphere[lower-alpha 3] | Mexico |
| SC (aq. solution) | 25 mg/vial | Prolutex | Europe |
| SC implant | 50, 100 mg | Proluton[lower-alpha 3] | Discontinued |
| IV (aq. solution) | 20 mg/mL | Primolut | Discontinued |
Sources and footnotes:
| |||
See also
- Progesterone (medication) § Available forms
- Pharmacokinetics of progesterone § Routes of administration
- Template:Available forms of estradiol
- Template:Available forms of testosterone
References
- ↑ "Drugs@FDA: FDA Approved Drug Products". United States Food and Drug Administration. Retrieved 26 July 2018.
- ↑ Engel J, Kleemann A, Kutscher B, Reichert D (14 May 2014). Pharmaceutical Substances, 5th Edition, 2009: Syntheses, Patents and Applications of the most relevant APIs. Thieme. pp. 1145–. ISBN 978-3-13-179275-4.
- ↑ Becker KL (2001). Principles and Practice of Endocrinology and Metabolism. Lippincott Williams & Wilkins. pp. 2168–. ISBN 978-0-7817-1750-2.
- ↑ Anita MV, Jain S, Goel N (31 July 2018). Use of Progestogens in Clinical Practice of Obstetrics and Gynecology. JP Medical Ltd. pp. 4–. ISBN 978-93-5270-218-3.
- ↑ Sauer MV (1 March 2013). Principles of Oocyte and Embryo Donation. Springer Science & Business Media. pp. 7, 117–118. ISBN 978-1-4471-2392-7.
- ↑ Elder K, Dale B (2 December 2010). In-Vitro Fertilization. Cambridge University Press. pp. 26–. ISBN 978-1-139-49285-0.
- ↑ https://web.archive.org/web/20191230051017/https://mx.prvademecum.com/medicamento/prosphere-11003/
- ↑ Heinrich Kahr (8 March 2013). Konservative Therapie der Frauenkrankheiten: Anzeigen, Grenzen und Methoden Einschliesslich der Rezeptur. Springer-Verlag. pp. 21–. ISBN 978-3-7091-5694-0.
- ↑ Basic Sex Hormone Therapy. Schering A.G. 1962. p. 96.
- ↑ Current Medicine and Drugs. 1962. p. 40.
Primolut Intravenous (Schering A.G. Berlin)
- ↑ Haleem S, Khan MI (March 2015). "Changing Indian Market Trends of NMP: A Review" (PDF). International Journal of Pharma Research & Review. 4 (3): 28–30. ISSN 2278-6074.
| Editors can experiment in this template's sandbox (create | mirror) and testcases (create) pages. Subpages of this template. |